CD19 and acute lymphoblastic leukemia: Xenograft models derived from different cell lines injected subcutaneously (BL: Raji, Ramos, Namalwa; DLBCL: SU-DHL-6; acute lymphoblastic leukemia: SUP-B15) demonstrated significant lymphoma inhibition by XmAb5574, an anti-CD19 mAb with an Fc-engineered domain for effector function improvement.